An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes

Transactions of the American Ophthalmological Society

Volumn 105, Issue , 2007, Pages 54-59

  Augsburger, James J ^a   Corrêa, Zélia M ^a   Trichopoulos, Nikolaos ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CAUSE OF DEATH; CHOROID MELANOMA; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; MEDICAL LITERATURE; METASTASIS; MONOSOMY; MONOSOMY 3; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PUBLICATION; TUMOR LOCALIZATION; TUMOR VOLUME;

CHOROID NEOPLASMS; CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; HUMANS; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 47749101182     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol 1979;87:741-760.
2. Zimmerman LE. Metastatic disease from uveal melanomas. A review of current concepts with comments concerning future research and prevention. Trans Ophthalmol Soc U K 1980;100:34-54.
3. Augsburger JJ. Impact of enucleation on survival in posterior uveal melanoma: a reappraisal of the Zimmerman hypothesis. In: Laibson PR, ed. The Year Book of Ophthalmology. St. Louis: Mosby; 1991:123-126.
4. Callender GR, Wilder HC, Ash JE. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol 1942;25:962-967.
5. Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin 1962;2:387-403.
6. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:123-132.
7. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983;101:1894-1899.
8. Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 1990;66:1596-1600.
9. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand 1995;73:340-344.
10. Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Arch Ophthalmol 2005;123:1639-1643.
11. Callender GR. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 1931;36:131-140.
12. McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender's spindle A type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol 1978;86:557-564.
13. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classifications of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-509.
14. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100:1389-1398.
15. Warren RM. Prognosis of malignant melanomas of the choroid and ciliary body. In: Blodi FC, ed. Current Concepts in Ophthalmology. Vol 4. St Louis: Mosby; 1974:158-166.
16. Shammas HF, Blodi FC. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 1977;95:63-69.
17. Horsthemke B, Prescher G, Bornfeld N, Becher R. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer 1992;4:217-221.
18. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet 1995;80:40-46.
19. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83:354-359.
20. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Nat Cancer Inst 1999;82:1765-1769.
21. Sisley K, Parsons MA, Garnham J, et al. Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 2000;82:330-338.
22. Baggetto LG, Gambrelle J, Dayan G, et al. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects. Cancer Treat Rev 2005;31:361-379.
23. Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci 2006;47:3703-3707.
24. Cross NA, Ganesh A, Parpia M, Murray AK, Rennie IG, Sisley K. Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma. Eye 2006;20:476-481.
25. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-1225.
26. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22-28.
27. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:313-317.
28. Sandinha MT, Farquharson MA, Roberts F. Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation. Br J Ophthalmol 2004;88:1527-1532.
29. Damato B. Developments in the management of uveal melanoma. Clin Exp Ophthalmol 2004;32:639-647.
30. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 2005;46:2253-2257.
31. Sandinha MT, Farquharson MA, McKay IC, Roberts F. Monosomy 3 predicts death but no time until death in choroidal melanoma. Invest Ophthalmol Vis Sci 2005;46:3497-3501.
32. Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L, et al. Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. J Fr Ophtalmol 2006;29:741-749.
33. Harbour JW. Eye cancer: unique insights into oncogenesis: the Cogan Lecture. Invest Ophthalmol Vis Sci 2006;47:1736-1745.
34. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003;44:1008-1011.
35. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-7209.
36. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 2005;140:748-749.
37. Cross NA, Rennie IG, Murray AK, Sisley K. The identification of chromosome abnormalities associated with the invasive phenotype of uveal melanoma in vitro. Clin Exp Metastasis 2005;22:107-113.
38. Naus NC, Verhoeven ACA, van Drunen E, et al. Detection of genetic prognostic markers in uveal melanoma using fluorescence in situ hydridization. Clin Cancer Res 2002;8;534-539.
39. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003;63:2578-2584.
40. Zuidervaart W, van der Velden PA, Hurks MH, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003;89:1914-1919.
41. Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004;10:1605-1612.
42. Boldin I, Langmann G, Richtig E, et al. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 2005;15:503-507.
43. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007;21:752-759.
44. Gamel JW, McLean IW. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993;71:2299-2305.